Added to YB: 2026-09-16
Pitch date: 2026-09-14
RNAC [bullish]
Cartesian Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases.
Market Cap
$247.8M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.79
P/E
-1.46
EV/Sales
111.06
Sector
Biotechnology
Category
growth
Week Ahead: Week of September 14 - Cartesian Therapeutics, Inc.
RNAC: Cartesian offers a diversified autoimmune pipeline ahead of a 2027 catalyst wall: Phase 3 Descartes-08 data in myasthenia gravis, two additional Descartes-08 readouts and initial data from a partnered in vivo CAR-T program. Roughly $149.3M of cash funds operations into 2028, while licensed Phase 2-ready SP001 adds a fifth program. The key risk is a long holding period without confirmatory data, though no single trial carries the thesis.
Read full article (1 min)